us en false false Default
Skip directly to Accessibility Notice
PPH VanEck Pharmaceutical ETF Please read important disclosure Close important disclosure Show More Show Less Compare false

PPH
VanEck Pharmaceutical ETF

PPH
VanEck Pharmaceutical ETF

  • NAV
    $108.15

    as of October 01, 2026
  • YTD RETURNS
    6.33%

    as of October 01, 2026
  • Total Net Assets
    $1.02B

    as of October 01, 2026
  • Total Expense Ratio
    0.36%
  • Inception Date
    12/20/2011

Overview

Why PPH

  • Highly Liquid CompaniesTracks the largest most liquid pharmaceutical companies
  • Industry LeadersFavors established industry leaders with meaningful scale
  • Global ScopeProvides exposure to U.S. and international equities for global industry representation

VanEck Pharmaceutical ETF (PPH®) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the MVIS® US Listed Pharmaceutical 25 Index (MVPPHTR), which is intended to track the overall performance of companies involved in pharmaceuticals, including pharmaceutical research and development as well a production, marketing and sales of pharmaceuticals.

Performance

Average Annual Total Returns* (%)

  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) 2.45 8.50 11.15 29.87 13.65 10.41 8.78 10.31
PPH (Market Price) 2.43 8.57 11.13 29.92 13.65 10.41 8.79 10.39
MVIS US Listed Pharmaceutical 25 Index 2.46 8.50 10.94 29.69 13.30 10.05 8.53 10.12
  1 MO 3 MO YTD 1 YR 3 YR 5 YR 10 YR LIFE 12/20/11
PPH (NAV) 4.42 5.83 6.97 27.15 13.83 10.55 8.46 10.15
PPH (Market Price) 4.40 6.13 6.86 27.12 13.83 10.52 8.46 10.22
MVIS US Listed Pharmaceutical 25 Index 4.38 5.74 6.73 26.87 13.35 10.15 8.20 9.95

Holdings

Daily Holdings (%) as of 10/01/2026

Download XLS Get holdings
Total Holdings: 26
Ticker
Holding Name
% of Net Assets
Market Value (US$)
LLY
Eli Lilly & Co
20.80
214,559,710
MRK
Merck & Co Inc
13.33
137,536,001
NVO
Novo Nordisk A/S
5.59
57,644,134
PFE
Pfizer Inc
5.15
53,085,217
BMY
Bristol-Myers Squibb Co
4.80
49,528,455
TEVA
Teva Pharmaceutical Industries Ltd
4.77
49,225,948
MCK
Mckesson Corp
4.61
47,579,936
GSK
Gsk Plc
4.44
45,791,823
COR
Cencora Inc
4.38
45,221,994
ABBV
Abbvie Inc
3.64
37,594,976
HLN
Haleon Plc
3.62
37,310,255
NVS
Novartis Ag
3.61
37,232,969
AZN
Astrazeneca Plc
3.54
36,466,706
JNJ
Johnson & Johnson
3.41
35,146,462
SNY
Sanofi Sa/France
3.34
34,444,114
TAK
Takeda Pharmaceutical Co Ltd
2.69
27,776,836
ZTS
Zoetis Inc
2.47
25,516,488
VTRS
Viatris Inc
1.50
15,425,858
JAZZ
Jazz Pharmaceuticals Plc
1.34
13,859,202
CORT
Corcept Therapeutics Inc
0.77
7,947,771
AXSM
Axsome Therapeutics Inc
0.73
7,551,171
ELAN
Elanco Animal Health Inc
0.49
5,044,392
DFTX
Definium Therapeutics Inc
0.49
5,029,226
OGN
Organon & Co
0.29
3,013,814
PRGO
Perrigo Co Plc
0.10
1,056,323
-USD CASH-
--
0.09
960,888
--
Other/Cash
-0.00
-26,796
← Scroll for more information →
These are not recommendations to buy or to sell any security. Securities and holdings may vary.

Portfolio

Sector Weightings (%) as at 08/31/2026

  • Sector

    % of Net Assets
  • Health Care

    99.79
  • Other/Cash

    0.21

Country Weightings (%) as at 08/31/2026

  • Country

    % of Net Assets
  • United States

    63.70
  • United Kingdom

    10.90
  • Switzerland

    9.98
  • Denmark

    4.91
  • France

    4.03
  • Israel

    3.15
  • Japan

    3.12
  • Other/Cash

    0.21

Fees

Distributions

  as of  10/01/2026


Distribution Frequency

Quarterly


30-Day SEC Yield

1.87%


Distribution Yield

1.33%


12 Month Yield

2.34%

Yield information reflects temporary waivers of expenses and/or fees. Yields would have been reduced had these fees/expenses been included. In the absence of temporary expense waivers or reimbursements, the 30-Day SEC Yield for VanEck Pharmaceutical ETF would have been 1.87% on 10/01/26. Distributions may vary from time to time.

Team

Resources

PPH